Skip to main content
Top
Published in: BMC Immunology 1/2012

Open Access 01-12-2012 | Research article

Human CD72 splicing isoform responsible for resistance to systemic lupus erythematosus regulates serum immunoglobulin level and is localized in endoplasmic reticulum

Authors: Yuki Hitomi, Takahiro Adachi, Naoyuki Tsuchiya, Zen-Ichiro Honda, Katsushi Tokunaga, Takeshi Tsubata

Published in: BMC Immunology | Issue 1/2012

Login to get access

Abstract

Background

CD72 is an inhibitory co-receptor expressed on B cells. We previously demonstrated significant association of the polymorphism of the CD72 gene with susceptibility to human systemic lupus erythematosus (SLE) in individuals carrying a SLE-susceptible FCGR2B genotype (FCGR2B-232Thr/Thr). The human CD72 locus generates a splicing isoform that lacks exon 8 (CD72Δex8) as well as full-length CD72 (CD72fl), and the CD72 polymorphism regulates exon 8 skipping.

Results

Here we demonstrated that individuals carrying the disease-protective CD72 genotype exhibit significantly lower serum immunoglobulin levels than do individuals carrying other CD72 genotypes (P < 0.05). Although expression level of CD72fl in the peripheral blood B cells was similar regardless of CD72 genotype, the protein level of CD72Δex8 was increased in individuals carrying the disease-protective CD72 genotype, suggesting a crucial role of CD72Δex8 in regulation of antibody production. By expressing these human CD72 isoforms in mouse cell lines, we further demonstrated that CD72Δex8 is accumulated in endoplasmic reticulum (ER) and fails to regulate BCR signaling whereas human CD72fl is efficiently transported to the cell surface and inhibits signaling through the B cell antigen receptor (BCR), as is the case for mouse CD72.

Conclusion

Human CD72 polymorphism appears to regulate antibody production as well as susceptibility to SLE by regulating expression of ER-localizing CD72Δex8.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nakayama E, von Hoegen I, Parnes JR: Sequence of the Lyb-2 B-cell differentiation antigen defines a gene superfamily of receptors with inverted membrane orientation. Proc Natl Acad Sci USA. 1989, 86: 1352-1356. 10.1073/pnas.86.4.1352.PubMedPubMedCentralCrossRef Nakayama E, von Hoegen I, Parnes JR: Sequence of the Lyb-2 B-cell differentiation antigen defines a gene superfamily of receptors with inverted membrane orientation. Proc Natl Acad Sci USA. 1989, 86: 1352-1356. 10.1073/pnas.86.4.1352.PubMedPubMedCentralCrossRef
2.
go back to reference Von Hoegen I, Nakayama E, Parnes JR: Identification of a human protein homologous to the mouse Lyb-2 B cell differentiation antigen and sequence of the corresponding cDNA. J Immunol. 1990, 144: 4870-4877.PubMed Von Hoegen I, Nakayama E, Parnes JR: Identification of a human protein homologous to the mouse Lyb-2 B cell differentiation antigen and sequence of the corresponding cDNA. J Immunol. 1990, 144: 4870-4877.PubMed
3.
go back to reference Beavil AJ, Edmeades RL, Gould HJ, Sutton BJ: α-Helical coiled-coil stalks in the low-affinity receptor for IgE (FcεRII/CD23) and related C-type lectins. Proc Natl Acad Sci USA. 1992, 89: 753-757. 10.1073/pnas.89.2.753.PubMedPubMedCentralCrossRef Beavil AJ, Edmeades RL, Gould HJ, Sutton BJ: α-Helical coiled-coil stalks in the low-affinity receptor for IgE (FcεRII/CD23) and related C-type lectins. Proc Natl Acad Sci USA. 1992, 89: 753-757. 10.1073/pnas.89.2.753.PubMedPubMedCentralCrossRef
4.
go back to reference Adachi T, Flaswinkel H, Yakura H, Reth M, Tsubata T: The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol. 1998, 160: 4662-4665.PubMed Adachi T, Flaswinkel H, Yakura H, Reth M, Tsubata T: The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol. 1998, 160: 4662-4665.PubMed
5.
go back to reference Adachi T, Wakabayashi C, Nakayama T, Yakura H, Tsubata T: CD72 negatively regulates signaling through the antigen receptor of B cells. J Immunol. 2000, 164: 1223-1229.PubMedCrossRef Adachi T, Wakabayashi C, Nakayama T, Yakura H, Tsubata T: CD72 negatively regulates signaling through the antigen receptor of B cells. J Immunol. 2000, 164: 1223-1229.PubMedCrossRef
6.
go back to reference Adachi T, Wienands J, Wakabayashi C, Yakura H, Reth M, Tsubata T: SHP-1 requires inhibitory co-receptors to down-modulate B cell antigen receptor-mediated phosphorylation of cellular substrates. J Biol Chem. 2001, 276: 26648-26655. 10.1074/jbc.M100997200.PubMedCrossRef Adachi T, Wienands J, Wakabayashi C, Yakura H, Reth M, Tsubata T: SHP-1 requires inhibitory co-receptors to down-modulate B cell antigen receptor-mediated phosphorylation of cellular substrates. J Biol Chem. 2001, 276: 26648-26655. 10.1074/jbc.M100997200.PubMedCrossRef
7.
go back to reference Hitomi Y, Tsuchiya N, Kawasaki A, Ohashi J, Suzuki T, Kyogoku C, Fukazawa T, Bejrachandra S, Siriboonrit U, Chandanayingyong D, et al: CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B. Hum Mol Genet. 2004, 13: 2907-2917. 10.1093/hmg/ddh318.PubMedCrossRef Hitomi Y, Tsuchiya N, Kawasaki A, Ohashi J, Suzuki T, Kyogoku C, Fukazawa T, Bejrachandra S, Siriboonrit U, Chandanayingyong D, et al: CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B. Hum Mol Genet. 2004, 13: 2907-2917. 10.1093/hmg/ddh318.PubMedCrossRef
8.
go back to reference Tsuchiya N, Honda Z, Tokunaga K: Role of B cell inhibitory receptor polymorphisms for systemic lupus erythematosus: a negative times a negative makes a positive. J Hum Genet. 2006, 51: 741-750. 10.1007/s10038-006-0030-4.PubMedCrossRef Tsuchiya N, Honda Z, Tokunaga K: Role of B cell inhibitory receptor polymorphisms for systemic lupus erythematosus: a negative times a negative makes a positive. J Hum Genet. 2006, 51: 741-750. 10.1007/s10038-006-0030-4.PubMedCrossRef
9.
go back to reference Wakabayashi C, Adachi T, Wienands J, Tsubata T: A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science. 2002, 298: 2392-2395. 10.1126/science.1076963.PubMedCrossRef Wakabayashi C, Adachi T, Wienands J, Tsubata T: A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science. 2002, 298: 2392-2395. 10.1126/science.1076963.PubMedCrossRef
10.
go back to reference Yan BC, Adachi T, Tsubata T: ER stress is involved in B cell antigen receptor ligation-induced apoptosis. Biochem Biophys Res Commun. 2008, 365: 143-148. 10.1016/j.bbrc.2007.10.137.PubMedCrossRef Yan BC, Adachi T, Tsubata T: ER stress is involved in B cell antigen receptor ligation-induced apoptosis. Biochem Biophys Res Commun. 2008, 365: 143-148. 10.1016/j.bbrc.2007.10.137.PubMedCrossRef
11.
go back to reference Tokunaga K, Imanishi T, Takahashi K, Juji T: On the origin and dispersal of East Asian populations as viewed from HLA haplotypes. Prehistoric Mongoloid Dispersals. Edited by: Akazawa T, Szathmary EJ. 1996, Oxford: Oxford University Press, 187-197. Tokunaga K, Imanishi T, Takahashi K, Juji T: On the origin and dispersal of East Asian populations as viewed from HLA haplotypes. Prehistoric Mongoloid Dispersals. Edited by: Akazawa T, Szathmary EJ. 1996, Oxford: Oxford University Press, 187-197.
12.
go back to reference Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A, Fukazawa T, Jansen MD, Hashimoto H, van de Winkel JG, Kallenberg CG, Tokunaga K: Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 2002, 46: 1242-1254. 10.1002/art.10257.PubMedCrossRef Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A, Fukazawa T, Jansen MD, Hashimoto H, van de Winkel JG, Kallenberg CG, Tokunaga K: Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 2002, 46: 1242-1254. 10.1002/art.10257.PubMedCrossRef
13.
go back to reference Delibrias CC, Floettmann JE, Rowe M, Dearon DT: Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes. J Exp Med. 1997, 186: 1575-1583. 10.1084/jem.186.9.1575.PubMedPubMedCentralCrossRef Delibrias CC, Floettmann JE, Rowe M, Dearon DT: Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes. J Exp Med. 1997, 186: 1575-1583. 10.1084/jem.186.9.1575.PubMedPubMedCentralCrossRef
14.
go back to reference Schwarting R, Castello R, Moldenhauer G, Pezzutto A, von Hoegen I, Ludwig WD, Parnes JR, Dörken B: Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias. Am J Hematol. 1992, 41: 151-158. 10.1002/ajh.2830410303.PubMedCrossRef Schwarting R, Castello R, Moldenhauer G, Pezzutto A, von Hoegen I, Ludwig WD, Parnes JR, Dörken B: Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias. Am J Hematol. 1992, 41: 151-158. 10.1002/ajh.2830410303.PubMedCrossRef
15.
go back to reference Schröder M, Kaufman RJ: The unfolded protein response in nutrient sensing and differentiation. Annu Rev Biochem. 2005, 74: 739-789. 10.1146/annurev.biochem.73.011303.074134.PubMedCrossRef Schröder M, Kaufman RJ: The unfolded protein response in nutrient sensing and differentiation. Annu Rev Biochem. 2005, 74: 739-789. 10.1146/annurev.biochem.73.011303.074134.PubMedCrossRef
16.
go back to reference Ron D, Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007, 8: 519-529. 10.1038/nrm2199.PubMedCrossRef Ron D, Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007, 8: 519-529. 10.1038/nrm2199.PubMedCrossRef
17.
go back to reference Wong WL, Brostrom MA, Kuznetsov G, Gmitter-Yellen D, Brostrom CO: Inhibition of protein synthesis and early protein processing by thapsigargin in cultured cells. Biochem J. 1993, 289: 71-79.PubMedPubMedCentralCrossRef Wong WL, Brostrom MA, Kuznetsov G, Gmitter-Yellen D, Brostrom CO: Inhibition of protein synthesis and early protein processing by thapsigargin in cultured cells. Biochem J. 1993, 289: 71-79.PubMedPubMedCentralCrossRef
18.
go back to reference Bertrand R, Solary E, O’Connor P, Kohn KW, Pommier Y: Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res. 1994, 211: 314-321. 10.1006/excr.1994.1093.PubMedCrossRef Bertrand R, Solary E, O’Connor P, Kohn KW, Pommier Y: Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res. 1994, 211: 314-321. 10.1006/excr.1994.1093.PubMedCrossRef
19.
go back to reference Smith AJ, Gordon TP, Macardle PJ: Increased expression of the B-cell-regulatory molecule CD72 in primary Sjögren’s syndrome. Tissue Antigens. 2004, 63: 255-259. 10.1111/j.1399-0039.2004.00187.x.PubMedCrossRef Smith AJ, Gordon TP, Macardle PJ: Increased expression of the B-cell-regulatory molecule CD72 in primary Sjögren’s syndrome. Tissue Antigens. 2004, 63: 255-259. 10.1111/j.1399-0039.2004.00187.x.PubMedCrossRef
20.
go back to reference van Vugt MJ, Reefman E, Zeelenberg I, Boonen G, Leusen JH, van de Winkel JG: The alternatively spliced CD64 transcript FcγRIb2 does not specify a surface-expressed isoform. Eur J Immunol. 1999, 29: 143-149. 10.1002/(SICI)1521-4141(199901)29:01<143::AID-IMMU143>3.0.CO;2-#.PubMedCrossRef van Vugt MJ, Reefman E, Zeelenberg I, Boonen G, Leusen JH, van de Winkel JG: The alternatively spliced CD64 transcript FcγRIb2 does not specify a surface-expressed isoform. Eur J Immunol. 1999, 29: 143-149. 10.1002/(SICI)1521-4141(199901)29:01<143::AID-IMMU143>3.0.CO;2-#.PubMedCrossRef
21.
go back to reference Jaskolski F, Normand E, Mulle C, Coussen F: Differential trafficking of GluR7 Kainate receptor subunit splice variants. J Biol Chem. 2005, 280: 22968-22976. 10.1074/jbc.M413166200.PubMedCrossRef Jaskolski F, Normand E, Mulle C, Coussen F: Differential trafficking of GluR7 Kainate receptor subunit splice variants. J Biol Chem. 2005, 280: 22968-22976. 10.1074/jbc.M413166200.PubMedCrossRef
22.
go back to reference Zarei MM, Zhu N, Alioua A, Eghbali M, Stefani E, Toro L: A novel MaxiK splice variant exhibits dominant-negative properties for surface expression. J Biol Chem. 2001, 276: 16232-16239. 10.1074/jbc.M008852200.PubMedCrossRef Zarei MM, Zhu N, Alioua A, Eghbali M, Stefani E, Toro L: A novel MaxiK splice variant exhibits dominant-negative properties for surface expression. J Biol Chem. 2001, 276: 16232-16239. 10.1074/jbc.M008852200.PubMedCrossRef
23.
go back to reference Kono H, Kyogoku C, Suzuki T, Tsuchiya N, Honda H, Yamamoto K, Tokunaga K, Honda Z: FcγRIIb Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet. 2005, 14: 2881-2892. 10.1093/hmg/ddi320.PubMedCrossRef Kono H, Kyogoku C, Suzuki T, Tsuchiya N, Honda H, Yamamoto K, Tokunaga K, Honda Z: FcγRIIb Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet. 2005, 14: 2881-2892. 10.1093/hmg/ddi320.PubMedCrossRef
24.
go back to reference Fukuyama H, Nimmerjahn F, Ravetch JV: The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol. 2005, 6: 99-106.PubMedCrossRef Fukuyama H, Nimmerjahn F, Ravetch JV: The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol. 2005, 6: 99-106.PubMedCrossRef
25.
go back to reference Deng Y, Tsao BP: Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010, 6: 683-692. 10.1038/nrrheum.2010.176.PubMedPubMedCentralCrossRef Deng Y, Tsao BP: Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010, 6: 683-692. 10.1038/nrrheum.2010.176.PubMedPubMedCentralCrossRef
26.
go back to reference Goldstein DB: Common genetic variation and human traits. N Engl J Med. 2009, 360: 1696-1698. 10.1056/NEJMp0806284.PubMedCrossRef Goldstein DB: Common genetic variation and human traits. N Engl J Med. 2009, 360: 1696-1698. 10.1056/NEJMp0806284.PubMedCrossRef
27.
go back to reference Cirulli ET, Goldstein DB: Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet. 2010, 11: 415-425. 10.1038/nrg2779.PubMedCrossRef Cirulli ET, Goldstein DB: Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet. 2010, 11: 415-425. 10.1038/nrg2779.PubMedCrossRef
28.
go back to reference Wang GS, Cooper TA: Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007, 8: 749-761. 10.1038/nrg2164.PubMedCrossRef Wang GS, Cooper TA: Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007, 8: 749-761. 10.1038/nrg2164.PubMedCrossRef
Metadata
Title
Human CD72 splicing isoform responsible for resistance to systemic lupus erythematosus regulates serum immunoglobulin level and is localized in endoplasmic reticulum
Authors
Yuki Hitomi
Takahiro Adachi
Naoyuki Tsuchiya
Zen-Ichiro Honda
Katsushi Tokunaga
Takeshi Tsubata
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2012
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-13-72

Other articles of this Issue 1/2012

BMC Immunology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine